Abstract: TH-PO996
Study of Long-Term Recurrence and Adverse Effects of Rituximab Treatment in Adults with Steroid-Dependent Minimal-Change Nephrotic Syndrome
Session Information
- Glomerular Diseases: Minimal Change Disease, FSGS, IgAN
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Yamaguchi, Erika, Tokyo Women's Medical University, Tokyo, Japan
- Iwabuchi, Yuko, Tokyo Women's Medical University, Shinjuku-ku, TOKYO, Japan
- Karasawa, Kazunori, Department medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan
- Moriyama, Takahito, Tokyo Women's Medical University, Shinjuku-ku, TOKYO, Japan
- Nitta, Kosaku, Tokyo Women's Medical University, Shinjuku-ku, TOKYO, Japan
Background
The effect of rituximab treatment on the minimal-change nephrotic syndrome came to be known widely. However, there are few reports about the long term clinical course after rituximab treatment. Therefore, we studied a 60-month recurrence and the adverse effects from start of the rituximab treatment.
Methods
We performed a retrospective study of the clinical course of 52 MCNS patients who had rituximab treatment at interval of 6 months. We compared the clinical findings between the 60-month period before and 60-month period after the first rituximab infusion.
Results
Significant reduction in the average number of relapses was observed during the 60-month period after the first rituximab infusion as compared with the findings during the 60-month period before the first rituximab infusion (8.9 vs 0.7, p<0.001). Oral administration of immunosuppressant containing prednisolone at 60-month was significantly decrease from the start of rituximab. There were no severe adverse effects during the 60 month period after the first rituximab. However, mild infusion reactions occurred 60 times (14.4%). Also, two patients had leukopenia (3.8%), another one had myocarditis (1.9%), another one had buttocks abscess (1.9%), and another two patients had hypogammagolbulinemia (3.8%).
Conclusion
Our results revealed that rituximab therapy was associated with reduction in the number of relapses and in the total dose of immunosuppressant needed. And the results also revealed that rituximab was safe for MCNS patients. However a few patients had some adverse events, so it is important to observe all patients after rituximab treatment regularly.